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a n a ly s i s
The genetic architecture of human diseases governs the success of genetic mapping and the future of personalized medicine. Although numerous studies have queried the genetic basis of common disease, contradictory hypotheses have been advocated about features of genetic architecture (for example, the contribution of rare versus common variants). We developed an integrated simulation framework, calibrated to empirical data, to enable the systematic evaluation of such hypotheses. For type 2 diabetes (T2D), two simple parameters-(i) the target size for causal mutation and (ii) the coupling between selection and phenotypic effect-define a broad space of architectures. Whereas extreme models are excluded by the combination of epidemiology, linkage and genome-wide association studies, many models remain consistent, including those where rare variants explain either little (<25%) or most (>80%) of T2D heritability. Ongoing sequencing and genotyping studies will further constrain the space of possible architectures, but very large samples (for example, >250,000 unselected individuals) will be required to localize most of the heritability underlying T2D and other traits characterized by these models.
The genetic architecture of human diseases-that is, the number, frequencies and effect sizes of causal alleles-has profound implications for the future of genetic research and its impact on clinical medicine. Targeting for diagnosis and therapeutics based on the genome sequence of an individual will be more tractable for diseases caused by rare mutations of large effect than for diseases where many genes and variants together contribute [1] [2] [3] [4] . Similarly, the efficiency and power of research study designs [5] [6] [7] [8] and analytical methods 9, 10 depend critically on the underlying distribution of causal allele frequencies and effect sizes.
Complex disease architecture can be examined via several methods: epidemiological studies of twin and sibling concordance [11] [12] [13] [14] , familybased linkage scans [15] [16] [17] , genome-wide association studies (GWAS) 7 , including 'polygene' analyses combining data from large numbers of common variants 18, 19 , and (more recently) genome sequencing in phenotyped individuals [20] [21] [22] [23] [24] [25] . Each individual study design, however, provides a limited glimpse into the full architecture of a given trait, and, so far, only ~5-20% of heritability for most common diseases has been explained (largely by loci identified in GWAS) 26, 27 .
There has been much focus on this so-called 'missing heritability' of disease 28 . Some have argued that the unexplained heritability lies in a large number of common, individually weak alleles 18, 19, 29, 30 . Conversely, the numerous rare variants identified by exome sequencing studies [31] [32] [33] [34] [35] have been interpreted as evidence that rare alleles explain the majority of heritability. It has also been proposed that hundreds of rare monogenic subphenotypes may exist for each common disease [36] [37] [38] and that GWAS signals may actually represent 'synthetic' associations caused by rare causal mutations segregating on the background of common haplotypes 39 . Others have suggested effects related to epistasis, epigenetics or parent of origin 27, 40, 41 .
To systematically evaluate these and other hypotheses, it is necessary to compare the predictions of each model to empirical data from not just one but all available genetic studies in a unified framework. Here we asked which models are consistent with the cumulative results of studies already performed and which models can be excluded. Are models where common variants predominate plausible, despite the large number of rare alleles segregating in human populations? Are rare variant models compatible with the generally negative findings of family-based linkage studies and the numerous disease loci found in GWAS?
To address these questions, we developed a population genetic framework to directly simulate, in large populations, a wide space of genetic architecture. Focusing on the test case of T2D, we quantitatively evaluate each hypothesis about genetic architecture by simulating genetic studies as they were conducted for T2D and asking whether simulated results are consistent with empirical observations.
RESULTS

Simple models of complex diseases
The genetic architecture of any trait has, by necessity, been shaped by population genetic forces. Mutations at some (but not all) genomic loci have the potential to alter disease risk (we refer to these loci as disease 'targets'). Genetic drift and gene flow, influenced by demographic history and population migration, cause fluctuations in allele Evaluating empirical bounds on complex disease genetic architecture frequency independent of phenotype. Finally, natural selection results in directional changes in the frequency of alleles that influence evolutionary fitness, which is itself a composite of many traits (including, potentially, the disease of interest).
Analytical or simulation-based models have yielded insight into the qualitative dependence of genetic architecture (usually at single loci) on subsets of these parameters 10, [42] [43] [44] [45] [46] [47] . For example, explosive population growth after a bottleneck can allow even deleterious, disease-conferring alleles to become common in the population 45 . Conversely, strong selection against disease 47 or high mutation rates coupled with mild selection 46 could, in principle, enable rare alleles to explain most of heritability.
To quantitatively investigate the extent to which such models are consistent with emerging data from association studies and population-based sequencing, we performed simulations that enabled granular predictions of genome-wide genetic architecture and study results. Although the number of disease model parameters is potentially without bound, we sought to generate the simplest possible models by considering only mutations (of additive effect), genetic drift and purifying selection. If such simple models produce predictions inconsistent with empirical data, this does not imply that more complex models would not be consistent. However, if a simple model is consistent, then we can conclude that its features are indeed plausible, given current data.
On the basis of these considerations, we developed a three-stage framework: (i) forward evolutionary simulation to generate multilocus DNA sequence variation on a large scale (in hundreds of thousands of individuals) that is consistent with empirical sequencing data, (ii) mapping of genotype to phenotype under a range of disease models and (iii) in silico prediction of genetic study results under each model (Fig. 1) . For simplicity, our analysis focuses on Northern European populations.
Stage 1: simulation of DNA variation at the population scale Four main processes determine the spectrum of DNA variation: (i) mutation, (ii) demographic history (including genetic drift and migration) and (iii) natural selection on segregating alleles. To fit values for these parameters, we generated forward simulations of thousands of unlinked loci resembling protein-coding genes in 500,000 individuals using the software ForSim (Supplementary Fig. 1 ) 48 .
We initially parameterized simulations using previously published demographic histories 9, 49, 50 and then tested a grid over parameter space (Supplementary Table 1 ) to find the best fit to empirical data; for comparison, we also tested a naive history of constant population size (N = 10,000). Specifically, we asked whether simulated site frequency spectra (SFS) under each history matched the empirical SFS of synonymous sites (assumed to be evolutionarily neutral) observed in 1,322 European exomes sequenced by the GoT2D Consortium (Fig. 2a,b and Supplementary Figs. 2-4) . The best match to empirical data was produced by a 'hybrid' model with features of two published histories (parameters for history A are shown in Fig. 2) ; this model recapitulated the number and frequency distributions of both rare and common synonymous sites (Fig. 2b) , as well as empirically observed patterns of linkage disequilibrium (LD) between common variants ( Fig. 2e and Supplementary Fig. 5 ).
We next fit the distribution of purifying selection on proteincoding mutations by performing forward simulations under history A while applying per-variant selection coefficients drawn from a range of gamma distributions (as in previous reports 9, 51 , we assume that ~20% of nonsynonymous sites are neutrally evolving). The best-fit gamma distribution produced an SFS closely matching that for nonsynonymous sites in empirical data (Fig. 2c,d and Supplementary Figs. 6 and 7) . We model all loci as being under the same distribution of purifying selection (of strength comparable to selection against protein-coding changes). This simplifying 
Figure 1
Framework for specification and evaluation of disease models. a n a ly s i s npg a n a ly s i s assumption is likely reasonable for at least a portion of conserved noncoding regulatory elements 52 , but future work will consider selection distributions matched to different classes of biologically functional loci. A few simple evolutionary parameters could produce sequence variation (Fig. 2) , consistent with results from a large-scale exome sequencing study (parameters available as a ForSim configuration file). We next used these simulations to explore the relationship between allele frequency and the selection coefficient against a functional allele. There has been much recent debate, based on abundant rare variation observed in sequencing studies 8, 34 , about what fraction of deleterious variation is rare and, conversely, what fraction of rare variation is deleterious. Under our simulations, we found that, whereas >90% of deleterious nonsynonymous variants (selection coefficient (s) > 0.0005) are indeed rare (minor allele frequency (MAF) < 0.1%; Supplementary Fig. 8 ), fewer than 45% of all rare nonsynonymous variants are deleterious (consistent also with empirical estimates using prediction tools such as PolyPhen 34 ). Thus, most rare variants are simply of recent age (Supplementary Figs. 9 and 10) , and it would be inappropriate to infer functional consequence on the basis of frequency alone.
Stage 2: specification of disease models
Under an additive liability threshold model, the relationship between genotype and phenotype is controlled by (i) the number of disease-conferring variants each individual carries, (ii) the effects of causal variants on disease (these effects may or may not be related to variant selection coefficients), (iii) the magnitude of non-genetic (for example, environmental) influences and (iv) the liability threshold above which disease ensues. By varying these parameters it is possible to model a principled distribution of frequencies and effect sizes for causal variants rather than specifying them ad hoc.
To map genotype to phenotype for a specific disease, we focused on T2D. The prevalence of T2D (~8%; ref. 53) determines the liability threshold, and the heritability (~45%; estimated from family studies 54 ) determines the magnitude of genetic (compared to environmental) effects ( Supplementary Fig. 11 and Supplementary Note). We confirmed that the heritability for T2D specified under each disease model could be recovered via phenotypic regression and analysis of variance in full sibling pairs sampled from simulated populations (Supplementary Fig. 12 ).
The number of disease-conferring variants carried by an individual is determined by the mutational target size (T), or the sum total of a b npg a n a ly s i s nucleotides that, if mutated, would influence risk of disease. In the current study, we assume that causal mutations occur only at sites under evolutionary constraint similar to that at nonsynonymous changes under purifying selection; thus, only protein-coding loci and some conserved noncoding regions 55, 56 (collectively spanning ~10% or ~300 Mb of the human genome 52, 57 ) contribute to disease. We simulated models with T ranging from 75 kb to 3.75 Mb, corresponding to 0.02-1.2% of constrained genome sequence. To model linkage between variants at structurally contiguous regions, we grouped the disease target into loci (N = 30, 100, 300, 500, 800 or 1,500 causal loci in each model). Each locus contained 2.4 kb of functional target (under selection) flanked by neutrally evolving regions ( Supplementary Fig. 1 ).
Whereas purifying selection against lethal mendelian diseases is direct and evident, the relationship between selection and postreproductive common diseases is less clear. We therefore modeled apparent selection, where fitness is a composite of many traits, with a range of possible mappings between a variant's effect on fitness (measured by s) and its effect on a particular disease (g). We model this relationship with a single parameter (τ), which quantifies this coupling: g = s τ (Eyre-Walker 47 ). We performed simulations with τ = 0, 0.1, 0.2, 0.3, 0.4, 0.5 and 1. Where τ = 1 (tightly coupled), variants with large effects on fitness have large effects on disease. Where τ = 0 (uncoupled), there is no relationship between the selection coefficients of causal mutations and the impact of these mutations on the disease of interest (Supplementary Fig. 13 ).
Genetic architecture resulting under each disease model
We first verified that models in the two-dimensional parameter space (of T and τ) produced architectures with qualitative features consistent with analytical expectations.
We first asked how effects sizes for rare and common variants compared under different models. Under tightly coupled (τ = 1) models, rare variants (those under strong purifying selection) had much larger effects than common variants, whereas, under uncoupled (τ = 0) models, rare and common variants had comparable phenotypic effects ( Supplementary Figs. 13 and 14) . In contrast, the target size did not affect the relative effect sizes of rare and common variants; rather, increases in target size reduced the effects of causal variants across the entire frequency spectrum. This reduction in effect sizes occurs because T2D prevalence and heritability are fixed, meaning that a larger number of causal variants must be counteracted by smaller per-variant effects ( Fig. 3a and Supplementary Table 2) . Notably, under all models, the high prevalence and modest heritability of T2D constrained common (MAF > 5%) variants to odds ratios of <2, even at relatively small target sizes (for example, T = 75 kb).
Next, we asked how disease heritability is partitioned by allele frequency across models. The contribution of each causal variant to heritability (population genetic variance) is calculated by V a = 2 × (g 2 ) × (1 − f) × f (ref. 58) , where g is a variant's additive effect and f is its frequency. Under tightly coupled (τ = 1) models where g is very large for some rare alleles (often private to cases), the rare class (MAF < 1%) collectively explained >90% of heritability. Conversely, under uncoupled models (τ = 0), common alleles (MAF > 5%) with modest effects (odds ratio < 1.2) explained ~95% of heritability (Fig. 3b,c and Supplementary Fig. 15 ). These relationships held regardless of target size.
Finally, we examined the distribution of variant effects within each individual (rather than across the population) to evaluate the potential for individualized risk prediction under varied models of disease. Under tightly coupled models, individuals with T2D had few (1-5) high-effect risk alleles that were rarely seen in unaffected individuals. Conversely, under weakly coupled models with similar target size, each individual with T2D had hundreds of risk alleles with similar individual and cumulative effect (Supplementary Figs. 16 and 17) ; moreover, most of these variants were also commonly observed in controls. Thus, for a given target size, genetic risk prediction will be far more informative (diagnostic for some patients, assuming effects at rare alleles can be discovered and accurately quantified) if there is strong coupling to selection. This finding confirms the widely discussed intuition that, under rare variant models of common disease (e.g., where there is purifying selection against disease alleles), sequencing studies may greatly enhance clinical prediction.
In summary, simple disease models with only two free parameters (target size and coupling to selection) generate diverse genetic architectures ( Fig. 3c) with qualitative features consistent with previous expectations.
Stage 3: simulation of genetic study results
We next addressed our main question: which models produce genetic study results that are compatible with observed data in genetic studies of T2D?
To define the set of genetic studies to simulate, we collated results from published studies of T2D in European populations. These data included (i) epidemiological estimates of sibling relative risk (λ s of ~1. Table 3) ; and (vi) polygene score logistic regression 18 using thousands of common marker effects learned in the discovery GWAS (together explaining 2.0-2.5% of test sample variance, measured by Nagelkerke's R 2 ) 19 .
We simulated over 50 distinct disease models spanning a range of target sizes and selection parameters (Fig. 4a) . Under each model, we performed the above genetic studies, matching assay type and effective sample size (rather than total sample size, owing to cohort structure; Supplementary Table 3) to empirical studies. Each simulated study was analyzed without knowledge of which variants were causal (as would be the case in an actual study). As expected, the results for each study depended heavily on the genetic architecture (Fig. 4b,c and Supplementary Figs. 18 and 19) .
We first evaluated tightly coupled (τ = 1) models for consistency with empirical T2D data (Fig. 5a,b) . These models produced relatively high sibling relative risk (λ s = 4.2) due to rare, high-effect mutations shared by ASPs. Linkage peaks (LOD > 3.0) in simulated ASP studies were rarely observed, however, and only occurred with small target sizes: 90% of replicates under models with T < 75 kb (N < 30 loci) yielded a linkage peak, whereas fewer than 20% did with T > 250 kb (N = 100 loci). Thus, whereas empirical linkage data (where no LOD of >2.2 was observed) can exclude oligogenic, tightly coupled hypotheses, they cannot rule out models with larger mutational target sizes. GWAS results, however, are sufficient to exclude all tightly coupled models, regardless of target size: under complete coupling, too few causal variants are common enough to reach genome-wide significance, even after large-scale follow-up (4-5 loci when T = 250 kb compared to npg a n a ly s i s 39 loci in empirical data). Under tightly coupled models, polygene score regression is also less successful than empirically observed (R 2 < 0.5% compared to ~2% for T2D; Fig. 4 and Supplementary  Fig. 18) . A mixed linear modeling approach using common SNPs 65 similarly recovers a much smaller fraction (<10%) of T2D heritability than has been empirically reported 64 (Supplementary Fig. 19) .
Next, we evaluated uncoupled (τ = 0) hypotheses. These models produce modest risk to siblings (λ s ≈ 2) and lack positive linkage results (for T > 250 kb), consistent with observed data. However, across a wide range of uncoupled models (up to T = 3.75 Mb or N = 1,500 loci), an excess of GWAS findings is observed. An example of such a model (τ = 0, T = 1.25 Mb or N = 500 loci) is shown in Figure 5d ; 11-19 GWAS loci were found in discovery data (compared to 2 in empirical data), 61-71 loci were found after replication (compared to 16 in empirical data) and 99-102 loci were found in the large-scale GWAS followed by Metabochip genotyping analysis (compared to 39 in empirical data). Under this uncoupled model, polygene score regression also explained a larger proportion of phenotypic variance than observed for T2D (R 2 > 10% at P < 1 × 10 −4 compared to ~2% in empirical data; Fig. 4 and Supplementary  Fig. 18 ). Thus, if there were no purifying selection against alleles causing T2D, GWAS would likely have identified more signals than have been empirically observed.
Although these extreme models of genetic architecture are inconsistent with empirical data, a broad continuum of intermediate models remains consistent (Fig. 4a) . This class of consistent models includes those with moderate coupling and smaller target sizes, as well as those with weak coupling and larger target sizes. Two examples are shown in Figure 5c (moderately coupled; τ = 0.5, T = 1.25 Mb or N = 500 loci) and Figure 5e (weakly coupled; τ = 0.1, T = 3.75 Mb or N = 1,500 loci). Predicted outcomes under both models were consistent with empirical data. However, these architectures had quite distinct properties: under the moderately coupled model, rare (MAF < 5%) alleles explained ~80% of heritability, whereas, npg a n a ly s i s under the weakly coupled model, rare variants explained <25% of heritability (Supplementary Fig. 15 ).
Prediction of results from future studies
Ongoing genetic studies of T2D are using new assay technologies such as (i) exome and whole-genome sequencing and (ii) genotyping via an exome array to study rare variants and those of intermediate frequency in modest (thousands) and large (tens of thousands) samples, respectively. In coming years, it is predicted that sequencing will be performed in hundreds of thousands or even millions of people. It remains to be determined to what extent these ongoing and future studies will further constrain T2D genetic architecture.
We simulated high-coverage, whole-genome sequencing of 3,000 and 10,000 individuals (sample sizes similar to those of studies actively being performed for T2D by the GoT2D and T2D-GENES consortia, respectively), as well as a study in which a large proportion of rare coding variants are genotyped using an 'exome' array in 20,000 cases and 35,000 controls. In each study, we simulated single-variant association as well as gene-based association (Online Methods). To project studies that might be conducted in coming years, such as in the UK Biobank, we simulated complete genome sequencing of an unselected population cohort of 250,000 individuals (20,000 T2D cases and 230,000 controls).
We asked at what point disease models that are consistent with currently available data would diverge in future studies (Fig. 6) . As examples, we focused on the two consistent models depicted in Figure 5c (moderately coupled) and Figure 5e (weakly coupled). For both models, whole-genome sequencing in 3,000 individuals would discover few signals not previously detected by GWAS. With 10,000 samples, the models diverged slightly: ~15 novel loci (representing ~6% of heritability) were predicted under the moderately coupled model, whereas ~5 loci (representing <1% of heritability) were predicted under the weakly coupled model. The most significant constraint, however, is predicted to come from large exome array studies: ~80 npg a n a ly s i s novel loci were predicted under the moderately coupled model (bringing the cumulative heritability explained to ~50%), but only ~10 loci were predicted under the weakly coupled model (and ~15% of the cumulative heritability would be explained). Thus, at least one of these models will likely be inconsistent with the results of studies already planned for T2D.
As sample size was expanded in our simulations to 250,000 unselected individuals, these models diverged further. In both cases, substantial numbers of new loci were discovered, but the total fraction of heritability explained, as well as the frequency distribution of identified causal variants, differed. Under the moderately coupled model, over half (~265 of 500) of all disease-conferring loci would be discovered and would collectively explain ~75% of T2D heritability (Fig. 6a) . At a majority of loci, the variant with the strongest association with disease would be of low frequency (MAF < 2%). Under the weakly coupled model, a much larger fraction of disease-conferring loci would remain undetected (owing to the individually small effect sizes of many causal variants), and a smaller proportion of total heritability (~50%) would be explained (Fig. 6b) . However, the most associated variant at virtually all these loci would be common (MAF > 2%) and, thus, likely discoverable by GWAS of comparable sample size, without need for complete sequencing.
Thus, ongoing sequencing and genotyping studies (and the extent to which they are successful) will likely place substantial bounds on T2D genetic architecture. However, enumerating the full set of causal (N = 1,500 loci) , τ = 0.1 (weak coupling to selection). Red Xs indicate inconsistency with empirical data for T2D; green checkmarks indicate consistency with empirical data. Genome-wide significant loci represent the number of unique loci at which a variant is associated to disease at genome-wide significance levels (P < 5 × 10 −8 ). + , the value of sibling relative risk shown is the median across simulation replicates (s.d. shown in parentheses). ++ , the range across simulation replicates is shown (median replication values shown in parentheses). npg a n a ly s i s loci contributing to inherited risk of disease using a purely statistical approach will be extremely challenging, even in the limit of very large samples.
DISCUSSION
We developed a hypothesis testing framework, calibrated to empirical data, in which precisely defined disease models produce falsifiable predictions 66 about the results of genetic studies. Application of this framework to T2D excludes a subset of extreme architectures inconsistent with linkage, GWAS or polygene results but also identifies a range of consistent models with widely varying features. All simulated global and locus-level architectures (genotype and phenotype) under these consistent models are freely available for use in the development and evaluation of study designs or novel analytical methods.
The current study has many limitations. Although only two model parameters were sufficient to generate diverse architectures, more parameters could be included. For example, causal variants were simulated only at regions under purifying selection (alternate models where neutrally evolving alleles have effects on disease are explored in Supplementary Fig. 20) . Positive selection was not simulated, and derived alleles were only modeled as increasing disease risk (although, interestingly, this does not preclude the occurrence of significantly associated markers of protective effect, which may have implications for interpreting the direction of effect from GWAS associations; Supplementary Fig. 21) .
Additionally, locus structure in our study was uniform; heterogeneity in phenotypic contributions across loci arose only from stochastic sequence variation (Supplementary Fig. 22 ). Adding skew in the distribution of length, overall phenotypic contribution and coupling to selection across disease-related loci could produce more varied models. Finally, non-additive inheritance, epistasis and geneenvironment interactions were not modeled. In future work, if the outcomes of many genetic studies (such as those directly simulated here) in human populations can be accurately predicted using analytical solutions, an inferential approach could enable efficient traversal across disease models defined by many more variable parameters.
Nonetheless, in the current study, specifying simple parameters enabled us to systematically evaluate and characterize in depth a broad space of easily understood disease models. Although an infinite number of more complex models exist, a single simple model that produces results consistent with empirical data is alone sufficient to conclude that its properties currently remain plausible. Having found plausible models with widely varied genetic architectures, our results have a number of implications.
First, many specific hypotheses about genetic architecture cannot be adjudicated using single pieces of empirical data. For example, our results suggest that synthetic associations 39, 67, 68 , although rarely observed in simulations under consistent models, cannot be excluded only on the basis of the absence of linkage findings ( Supplementary  Fig. 23 ). Linkage data, in fact, do not place substantial bounds on global T2D architecture; only oligogenic models in which variants in a single gene have very large effects (Supplementary Fig. 24 ) can be excluded because empirical studies were underpowered 69 to differentiate other models. Similarly, observation of numerous rare alleles in sequencing studies is not, by itself, evidence to support mendelian models of common disease.
Second, our work shows that even broad conclusions about the validity of the common disease, common variant (CDCV) and common disease, rare variant (CDRV) hypotheses 45, 46, 70 are prematureand, further, that answers may long remain elusive. For T2D, empirical data firmly exclude extreme models such as those where rare variants are entirely responsible for disease, but, even with only two free parameters, it is possible to generate models that are consistent with all available data and yet have nearly opposite properties with respect to the contributions of rare and common variants. Multiple recent studies 29, 30, 71, 72 have demonstrated that a large fraction (~50% on average 71 ) of common disease heritability is tagged by common markers, but our study suggests that these data may still be consistent with a significant causal role for rare variants ( Supplementary  Fig. 19) ; studies directly assaying such variation will provide further discriminatory power.
Finally, our simulations indicate that hundreds of thousands of individuals will be required to discover most of the genes underlying complex diseases such as T2D and that, even then, a substantial fraction of heritability (and causal loci) may remain undiscovered. This is not meant to be nihilistic-much has already been learned about the genes and biology underlying T2D, and our study suggests that, in coming years, a great deal more will be discovered, including further constraints on models of genetic architecture. However, the challenge of localizing disease heritability may simply be the expected Top charts show the cumulative fraction of disease loci discovered by each study design. Bottom charts show the cumulative fraction of population genetic variance (heritability) explained by loci uncovered in each study. A is a discovery GWAS in 10,000 samples, followed by B, a replication genotyping of top signals in 55,000 independent samples (as in Zeggini et al. 62 ); C is a large-scale GWAS with discovery in an effective sample size of ~30,000, followed by genotyping of all independent signals with P < 0.005 to yield a total effective sample size of ~`85,000 (as performed using the Metabochip in Morris et al. 64 ); D is high-coverage genome sequencing in 3,000 samples; E is highcoverage genome sequencing in 10,000 samples; F is genotyping in 20,000 cases and 35 controls of all rare variants seen ≥2 times in 5,000 controls (similar to the ExomeChip); and G is high-coverage genome sequencing in 20,000 cases and 230,000 controls (an unselected population cohort of 250,000 with T2D prevalence of 8%). Labels above the bars indicate the predicted number of novel loci (for example, not found in the previous studies) discovered at each step (Online Methods). Solid lines indicates true variance explained by those loci; dashed lines represent the fraction estimated using frequencies and odds ratios (estimated in the study) for the most associated single variant at each locus. A: 10,000 GWAS (discovery) B: 65,000 GWAS (replication) C: 85,000 GWAS D: 3,000 genome sequencing E: 10,000 genome sequencing F: 55,000 genotyping G: 250,000 genome sequencing npg a n a ly s i s
ONLINE METhODS
Forward simulation of population-scale data. Large populations were forward simulated according to a wide range of demographic histories and selection coefficient distributions (Supplementary Tables 1 and 2 ) using the publicly available software package ForSim. We varied demographic history parameters, including the mutation rate (µ), the recombination rate (R), the ancestral population size (N a ), the bottleneck population size (N b ), the duration (t e ) and rate (r e ) of exponential growth and the modern effective population size (N e ). Selection coefficient distributions were modeled as gamma distributions, with a shape and scale parameter; a grid of parameter values centered on values previously published by Kryukov et al. 9 was tested. Best-fit parameters were determined by repeatedly sampling individuals (n = 63, 243 and 1,322) from simulated populations and comparing the average sample SFS to the observed SFS in empirical data (n = 63 CEU (Utah residents of Northern and Western European ancestry) and n = 243 EUR (European) 1000 Genomes Project exome data for n = 1,300 Europeans in GoT2D exome data). Frequency spectra were compared by normalizing the mutation target to a length of 1 Mb and correcting for imperfect sensitivity in empirical data (Supplementary Note).
Simulated disease locus structure. Simulated disease loci were modeled as protein-coding loci (exons with causal variation alternating with neutrally evolving introns). Neutrally evolving target sequence of 100 kb in length was simulated on each end of the genes to facilitate downstream genetic studies requiring markers in a large window around causal loci.
Modeling of complex disease phenotype. Simulated genotypes were mapped to phenotype using an additive liability threshold model. Each variant is modeled as having additive effect (Eyre-Walker et al. 47 ). Here, g is the variant's effect on the quantitative trait underlying disease phenotype, and s is the selection coefficient under which that variant evolved. Each individual is assigned a total genetic phenotype G by summing effects across all variants for which an individual carries the novel allele across all disease-causing loci as G g
, where g ij is the effect of the ith variant at the jth locus at which individual k carries a disease-causing allele. Target size is represented by N, the total number of causal loci over which genetic effects is summed. These total genetic phenotypes are then converted to z scores, and environmental phenotypes E are randomly assigned to each individual such that the total fraction of phenotypic variance attributable to genetic risk is given by the disease heritability (h)
, where values of E are drawn from a normal distribution. The disease prevalence (8% for T2D) determines the threshold for P above which individuals are assigned categorical disease status. We repeated this full population-scale simulation of disease 25 times for each disease model (represented by a pairing of N and τ).
Simulation of linkage and sibling measurements. From each simulated population, we sampled 10,000 unrelated cases and controls. Because we simulate nuclear families with multiple offspring (mean of two offspring per mating) in each generation, knowledge of sibling genotype and phenotype is available in each simulation. For each of the sampled cases and controls, we asked whether the sibling was also affected with T2D. The fraction of siblings of cases who were affected divided by the fraction of the siblings of controls who were affected yields the sibling relative risk. To perform ASP linkage studies, we sample 4,200 sibling pairs (matching the size of the largest European ASP meta-analysis for T2D) in which both siblings were affected with T2D. SNP data provide a marker map that is significantly denser but less polymorphic than the microsatellite marker maps that were used in published studies. Thus, full sequence data were down-sampled across all causal loci; we included only variants with MAF > 5% and pairwise LD (measured by r 2 ) < 0.2. The software package MERLIN was used to conduct non-parametric linkage analysis. z scores resulting from such analyses are normally distributed; to generate LOD scores across 'background' non-causal loci, we randomly sampled 500 independent z scores from a normal distribution (representing a unique marker every ~5 Mb of the human genome, similar to typical microsatellite map densities) and converted these to LOD scores using the relation LOD = z 2 /(2 × ln(10)). We recorded the genome-wide maximum LOD score (across both causal and non-causal loci) in each simulated study. Simulated models yielding a sibling relative risk of 1.8-3.5 (similar to the range observed across epidemiological studies of T2D) and no genome-wide LOD score greater than 3.0 (the maximum LOD score observed for T2D was 2.2) were deemed consistent with empirical data for T2D.
Simulation of GWAS.
We simulated discovery phase GWAS for T2D (similar to DIAGRAM v1 stage 1) by sampling 4,549 cases with T2D and 5,579 controls from simulated populations under each disease model. To simulate commercial GWAS arrays, full sequence data across all causal loci were down-sampled; we included only variants with MAF > 5% and pairwise LD (measured by r 2 ) <0.5. We performed standard association analysis using PLINK software. To model markers across background non-causal loci, we randomly sampled P values between 0 and 1 to fill a total marker set of 2 million SNPs (in comparison, 2.2 million total SNPs were imputed in the DIAGRAMv1 study). We used the resulting distribution of genome-wide marker P values to generate quantile-quantile plots and Manhattan plots for comparison to empirical data. We recorded the number of unique loci at which a marker P value was <5 × 10 −8 . To simulate replication GWAS, we genotyped all markers from the discovery phase at which P was <0.0001 in 20,000 cases and 35,000 controls (with the effective sample size matched to that in DIAGRAMv1 replication) and performed association testing in this larger sample. Resulting P values were used to determine the number of unique genome-wide significant loci predicted under each disease model after replication. Finally, we simulated largescale GWAS in an effective sample size of ~35,000 total individuals, similar to DIAGRAMv3; we then simulated genotyping of all independent signals with P < 0.005 on a genotyping array such as the Metabochip in an effective sample size of ~85,000. When appropriate, sample sizes were corrected to account for imputation uncertainty, and P values were adjusted to account for genomic control corrections performed in the empirical studies. The number of loci discovered at each stage of the GWAS was compared to observed data for T2D from each published study (Supplementary Table 3 ). Simulated models yielding 1-4 genome-wide significant loci in the discovery phase (N = 10,000; 2 loci observed empirically for T2D), 10-30 genome-wide significant loci in the replication phase (N = 55,000; 16 loci observed empirically for T2D) and 25-65 genome-wide significant loci in large-scale meta-analysis (N = 85,000; 39 loci observed empirically for T2D) were deemed consistent with empirical data.
Polygenic risk score analysis. Polygene score analysis is a method to assess the aggregate predictive power of SNP alleles tested in a GWAS 18, 19 . We pruned common SNPs by LD, preferentially retaining the SNPs with lower discovery P values to obtain a set of independent, maximally associated markers. We used the P values and effect sizes from discovery GWAS to select subsets of SNPs reaching four different P GWAS thresholds (0.001, 0.01, 0.1 and 0.5). For each SNP set, we summed the log-odds-weighted risk allele counts for each individual in an independent test sample of 2,000 cases and 3,000 controls to assign each individual a polygene risk score. We then tested these risk scores for association with case-control status using logistic regression. The predictive power of the polygene score was measured by Nagelkerke's R 2 . Models yielding a Nagelkerke's R 2 value between 0.01 and 0.04 for all P GWAS thresholds were deemed consistent with empirical data for T2D (where Nagelkerke's R 2 was ~2-2.5% for all thresholds).
Prediction of results of pending sequencing and genotyping studies.
Whole-genome, high-coverage sequencing studies were simulated in matched case-control cohorts of 3,000 and 10,000 samples. Large-scale genotyping studies similar to ongoing studies with the exome array were simulated by sampling 20,000 cases and 35,000 controls and assaying all sites seen ≥2 times in a sample of 5,000 controls. In each cohort, we performed single-variant association testing of every assayed sequence variant across all causal loci; any locus with a variant achieving a P value of <5 × 10 −8 npg
